Passer au contenu
- Environmental impact measurement of drug substance and drug product manufacturing and their supply chains: Life Cycle Assessment (LCA), carbon footprint, and solvent, energy and waste mapping
- Predictive LCA approach for peptide manufacturing: turning complex supplier and production data into actionable sustainability metrics to compare routes, technologies and suppliers before scale-up
- Data-driven reduction roadmaps: identification of the process steps and inputs with the largest impact, and levers prioritised by environmental gain, cost, feasibility and quality or regulatory impact
- Sustainable supply chain management: sustainability criteria in CDMO and supplier selection (RFP questionnaires, ESG ratings and commitments), supplier data collection for Scope 3 reporting, and sustainability KPIs in development and supply agreements
- Sustainable operations: greener chemistry and technologies (solvent replacement and recycling, greener synthesis and purification) built into process development, scale-up and technology transfer, with the regulatory CMC strategy to implement the changes (comparability, control strategy, ICH Q12 post-approval changes)
- Support for manufacturing sites in quantifying and communicating the environmental performance of their manufacturing offer to biotech and pharma clients
